Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Acute Pain
Interventions: Morphine, Placebo; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Degenerative Lumbar Spinal Stenosis, Degenerative Disc Disease, Degenerative Spondylolisthesis, Degenerative Disease
Interventions: Ropivacaine, Epinephrine, Clonidine, and Ketorolac Injection Cocktail, Placebo; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteoporosis, Cerebral Palsy, Spina Bifida, Osteopenia, Osteogenesis Imperfecta
Interventions: pamidronate, saline; Drug · Other
Lead sponsor: University of New Mexico; Other
Eligibility: 4 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Metastatic Colorectal Cancer, Colorectal Cancer
Interventions: MORAb-004, Placebo, Best supportive care; Drug · Other
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 67
States / cities: Alhambra, California • Bakersfield, California • Burbank, California + 54 more

Conditions: Clostridium Difficile Infection
Interventions: C. difficile Toxoid Vaccine, Placebo: 0.9% normal saline; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 50 Years and older
Enrollment: 9,302 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 142
States / cities: Huntsville, Alabama • Mobile, Alabama • Flagstaff, Arizona + 124 more

Conditions: Chronic Tympanic Membrane Perforation
Interventions: Fibroblast Growth Factor 2, Saline control; Drug
Lead sponsor: D. Bradley Welling, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tourette Syndrome
Interventions: levodopa solution 2mg/ml for i.v. use, placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza, Human
Interventions: Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 16 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more

Conditions: Acute Myocardial Infarction
Interventions: CSL112, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 1,267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 48
States / cities: Birmingham, Alabama • Huntsville, Alabama • Concord, California + 43 more

Conditions: Prurigo Nodularis
Interventions: CDX-0159, Normal saline; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Tempe, Arizona • Miami, Florida • Troy, Michigan + 4 more

Conditions: Ankylosing Spondylitis
Interventions: ABY-035, Placebo; Drug
Lead sponsor: Inmagene LLC; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Glendale, Arizona • Canoga Park, California • Huntington Beach, California + 12 more

Conditions: Post Traumatic Stress Disorder
Interventions: Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Matching IV Placebo, Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm; Behavioral · Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Necrotizing Soft Tissue Infection, Sepsis
Interventions: HAT, Placebo; Drug
Lead sponsor: Ascension Health; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Wichita, Kansas

Conditions: Labor Pain
Interventions: Terbutaline, Fentanyl, 0.9% NaCl; Drug
Lead sponsor: Kai Schoenhage; Other
Eligibility: 18 Years to 53 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: Cutaneous Lupus Erythematosus
Interventions: PD-0360324, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 17
States / cities: Anniston, Alabama • Oxford, Alabama • Los Angeles, California + 13 more

Conditions: Rib Fractures
Interventions: Saline infusion, Lidocaine infusion; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza, Vaccine
Interventions: cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 39 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: COVID-19, SARS-CoV2
Interventions: SAB-185, Normal Saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota

Conditions: Subarachnoid Hemorrhage
Interventions: desferrioxamine (DFO), placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Inguinal Hernia
Interventions: 0.25% Bupivacaine, Placebo, TAP block; Drug · Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Thermal Hyperalgesia, Anxiety, Pain
Interventions: Ketamine, Placebo, Normal Saline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: COVID-19 Immunization, Influenza Immunization
Interventions: IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1), IIV-HD + rC19 (dose 2), IIV-HD + rC19 (dose 3), IIV-HD + rC19 (dose 4), Placebo (0.9% NaCl); Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 980 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 9 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Ozanezumab, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Boston, Massachusetts • Grand Rapids, Michigan • Syracuse, New York + 1 more

Conditions: Left Ventricular Diastolic Dysfunction
Interventions: BNP (nesiritide), Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Study to Examine Pain Relief With Supplemental Intrathecal Morphine in TKA Patients

Effect of RECK in Posterior Spinal Fusion

Prevention of Post Operative Bone Loss in Children

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

In-office Repair of Chronic Tympanic Membrane Perforations

Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

A Study of CDX-0159 in Patients With Prurigo Nodularis

ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis

Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.

HAT for the Treatment of Sepsis Associated With NASTI

Intravenous Terbutaline to Facilitate Labor Epidural Catheter Placement

A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

Transabdominal Plane (TAP) Blocks for Inguinal Hernia Repairs

A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.